Open-Label Extension Study of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 10 May 2019 The trial is completed in Finland according to European Clinical Trials Database
- 08 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2018 Planned End Date changed from 5 May 2020 to 18 Mar 2020.